Urinary tract infection (UTI) occurs in the bladder, urethra, ureter, and kidneys due to colonization of microbial pathogens in these parts. UTI infections can be complicated or uncomplicated, based on the severity of infection. Amoxicillin is a penicillin antibiotic used to treat UTIs and is one of the most commonly prescribed antibiotic for uncomplicated UTIs. Urinary tract infection is among the most common bacterial infections affecting millions of persons worldwide. Recurrent urinary tract infection is a major health issue in females across the globe. Patients with urinary catheter or spinal cord injury are most likely to contract complicated UTIs.
Among non-institutionalized geriatric population, UTIs are the second-most common infection and estimated to account for around 25% of all bacterial infections.
Market Value and Forecast
The global Urinary tract infection treatment market was valued at US$ 9.2 Bn in 2015, and is projected to expand at a CAGR of 2.1% over forecast period 2016–2026, owing to increasing incidence of UTIs and recurring UTIs, increasing use of urinary catheters, and other drainage devices.
Drivers and Trends
Incidence of chronic diseases are on the rise across the globe. Population with chronic diseases such as diabetes mellitus, chronic institutional residence, neurologic conditions, and chronic indwelling urinary catheterization are more susceptible to developing complicated urinary tract infections. These factors are expected to increase the number of UTI patients and is expected to boost growth of the UTI treatment market over the forecast period. Introduction of combination products to combat multi-drug resistant bacteria and expending indications for existing drugs are some key factors positively affecting market growth.
Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1340
Analysis by Region
The global urinary tract infection treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Japan and Middle East & Africa (MEA). In terms of value, the APEJ market has been estimated to dominate the global urinary tract infection treatment market in 2016, and is expected to witness highest CAGR of 2.4% over the forecast period. Markets in MEA, North America, and Western Europe are estimated to register higher CAGRs as compared to other regional markets. Revenue from the North America market is expected to expand at a CAGR of 2.0% over the forecast period. In North America, the quinolones segment is expected to register a CAGR of 2.6% to reach value of US$ 695.4 Mn by 2026 end.
Analysis by Drug Type
The global urinary tract infection treatment market is segmented into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, and other segments. Penicillin & combinations segment is further sub-segmented into amoxicillin, amoxicillin & clavulanate potassium, and others. Quinolones segment is further sub-segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, and others. Cephalosporin segment is further sub-segmented into ceftriaxone, cefuroxime, cefixime, and cephalexin. Aminoglycoside antibodies segment is further sub-segmented into amikacin and gentamicin. Quinolones segment is estimated to account for maximum revenue share in the global urinary tract treatment market.
Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-1340
Analysis by Indication
By indication, the global urinary tract infection treatment market is segmented into complicated urinary tract infection, recurring complicated urinary tract infection, uncomplicated urinary tract infection, and neurogenic bladder infection. The neurogenic bladder infections indication segment is expected to expand at a CAGR of 2.6% in terms of revenue over the forecast period. The uncomplicated urinary tract infection segment was estimated in 2015 to dominate the overall urinary tract infection treatment market and expected to expand at a healthy CAGR over the forecast period.
Analysis by Distribution Channel
By distribution channel, the global urinary tract infection treatment market is segmented into hospital pharmacies, gynecology and urology clinics, drug store, retail pharmacies, and online drug stores. The online drug stores distribution channel segment is expected to expand at a CAGR of 2.8% in terms of revenues over the forecast period. The retail pharmacies is estimated to dominate the overall urinary tract infection market and expected to expand at a healthy CAGR over the forecast period
Some of the key players identified in the global urinary tract infection market report include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and AstraZeneca plc. The report offers valuable insights into company-specific strategies related to the global urinary tract infection market, market consolidation initiatives, and analyses of the various market players’ specific strengths, weaknesses, opportunities, and threats.